Centessa IPO Presentation Deck

IPO Use of Proceeds: $285m offering Gross Proceeds of $285m, together with existing cash and cash equivalents², expected to fund Centessa's programs and working capital needs through mid-2023 assuming no attrition, no partnering proceeds and no new acquisitions 1. 2. Clinical Stage Subsidiaries Preclinical Stage Subsidiaries Working Capital & General Corporate Purposes Spend is net of expected UK R&D tax credits reimbursed in cash March 31" Cash and Cash Equivalents balance is $298.6m 3. Non-exhaustive Spend ¹ $110m $60m $45m $50m $200m Remainder . Use of Proceeds³ Continuation of Phase 3 safety study (ALERT) for lixivaptan, initiation of a Phase 3 pivotal trial (ACTION) Initiation of Phase 2 clinical trials for imgatuzumab Completion of ongoing Phase 1 for ZF874 and initiation of future clinical studies for ZF874; IND enabling studies and initiation of Phase 1 for ZF877 Completion of ongoing Phase 2a clinical trial, initiation of future clinical trials for SerpinPC Fund continued development of the other programs in our pipeline, including designing and conducting preclinical studies and clinical trials, as well as funding discovery, manufacturing, research and development; Working capital, and other general corporate purposes Build out and ongoing staffing and systems expenses related to our centralized operational and R&D support functions and the integration of operations at the Centessa Subsidiaries into our larger organization CENTESSA 31

View entire presentation